Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non–small Cell Lung Cancer
American Journal of Clinical Oncology: Cancer Clinical Trials - United States
doi 10.1097/coc.0b013e3182a46896
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2015
Authors
Publisher
Ovid Technologies (Wolters Kluwer Health)